Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TLL-018 in adults with moderate-to-severe chronic spontaneous urticaria inadequately controlled by second-generation H1 antihistamines
CTR20240829Phase 3Completed
- Sponsor
- Highlight Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of girocitinib in chronic idiopathic urticaria (CIU), urticaria, sponsored by Highlight Pharmaceutical. Started Mar 2024; status: completed.
02
Drugs
girocitinib
03
Conditions
chronic idiopathic urticaria (CIU)urticaria
Beyond the preview
Go deeper on CTR20240829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240829.